HC Wainwright initiated coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX - Free Report) in a report published on Monday, MarketBeat reports. The brokerage issued a buy rating and a $42.00 price objective on the stock. HC Wainwright also issued estimates for Edgewise Therapeutics' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.97) EPS and FY2029 earnings at $3.10 EPS.
EWTX has been the topic of a number of other research reports. Royal Bank Of Canada restated an "outperform" rating and set a $48.00 target price on shares of Edgewise Therapeutics in a report on Thursday, June 5th. Wedbush reissued an "outperform" rating and set a $43.00 price objective on shares of Edgewise Therapeutics in a research note on Monday, April 21st. Scotiabank cut shares of Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and decreased their price objective for the company from $50.00 to $14.00 in a report on Wednesday, April 2nd. Piper Sandler reiterated an "overweight" rating and issued a $51.00 target price on shares of Edgewise Therapeutics in a report on Wednesday, April 2nd. Finally, Guggenheim initiated coverage on shares of Edgewise Therapeutics in a research report on Wednesday, April 30th. They set a "buy" rating and a $41.00 price target on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.00.
Get Our Latest Report on Edgewise Therapeutics
Edgewise Therapeutics Stock Down 0.4%
EWTX stock traded down $0.06 during midday trading on Monday, reaching $12.96. The company's stock had a trading volume of 361,183 shares, compared to its average volume of 1,188,408. The business's 50-day simple moving average is $14.71 and its 200-day simple moving average is $20.82. Edgewise Therapeutics has a 52 week low of $10.60 and a 52 week high of $38.12. The stock has a market cap of $1.36 billion, a PE ratio of -8.36 and a beta of 0.25.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.02. As a group, equities analysts forecast that Edgewise Therapeutics will post -1.45 earnings per share for the current fiscal year.
Insider Buying and Selling at Edgewise Therapeutics
In other Edgewise Therapeutics news, General Counsel John R. Moore sold 1,930 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total transaction of $31,748.50. Following the completion of the transaction, the general counsel owned 6,531 shares in the company, valued at approximately $107,434.95. This trade represents a 22.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Joanne M. Donovan sold 5,187 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total transaction of $85,326.15. Following the completion of the transaction, the chief marketing officer owned 21,588 shares in the company, valued at approximately $355,122.60. The trade was a 19.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,258 shares of company stock valued at $234,544 over the last ninety days. Company insiders own 23.20% of the company's stock.
Hedge Funds Weigh In On Edgewise Therapeutics
Several large investors have recently added to or reduced their stakes in EWTX. Diadema Partners LP bought a new position in shares of Edgewise Therapeutics during the 4th quarter worth $36,000. GF Fund Management CO. LTD. bought a new position in shares of Edgewise Therapeutics in the 4th quarter worth $53,000. Jones Financial Companies Lllp purchased a new stake in Edgewise Therapeutics during the first quarter valued at about $47,000. Aquatic Capital Management LLC bought a new stake in Edgewise Therapeutics in the 4th quarter worth approximately $77,000. Finally, Allostery Investments LP bought a new stake in shares of Edgewise Therapeutics in the 1st quarter worth approximately $66,000.
Edgewise Therapeutics Company Profile
(
Get Free Report)
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
See Also

Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.